The federal Project Grant award of $1,348,274.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) is supporting research by Greenstone Biosciences, Inc. to elucidate the mechanistic pathways of LMNA cardiomyopathy and identify novel therapeutic compounds. The funding period runs from May 15, 2024 to May 14, 2028.
Greenstone Biosciences, a biotechnology company in Palo Alto, California, is leveraging advanced drug discovery and development technologies such as induced pluripotent stem cell (iPSC) technology, artificial intelligence, and machine learning to accelerate pharmaceutical research, particularly for rare genetic disorders. The grant supports the company's efforts to develop innovative screening methods and research platforms that utilize iPSC-derived organoids and AI/ML algorithms to identify novel therapeutic compounds, assess drug safety and efficacy, and explore mechanistic pathways of LMNA cardiomyopathy, with the goal of creating more efficient drug discovery processes and providing more personalized and precise medical treatments.
Generated 1/28/25, 6:56 AM